Oruka Therapeutics price target raised to $131 from $71 at Clear Street

Clear Street raised the firm’s price target on Oruka Therapeutics (ORKA) to $131 from $71 and keeps a Buy rating on the shares. The firm says the company’s interim EVERLAST-A P2a results met its “blue-sky scenario.” The readout “represents a step-change” versus IL-23 benchmarks and supports the thesis that higher-dose IL-23 inhibition can deliver enhanced efficacy without compromising safety, the analyst tells investors in a research note.